TPWA
ENTA icon

Twin Peaks Wealth Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76 Buy
+6
New +$80 ﹤0.01% 2267

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Twin Peaks Wealth Advisors's ENTA Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Enanta Pharmaceuticals (ENTA) in Q1 2026: 6 shares worth $76. The stake represents ﹤0.01% of the portfolio and ranks #2267 among its holdings.

132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Twin Peaks Wealth Advisors held 6 shares of Enanta Pharmaceuticals worth $76 as of Q1 2026.
  • Enanta Pharmaceuticals was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #2267 holding.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.